Respiratory failure requiring orotracheal intubation (OTI) and mechanical ventilation (MV) is almost always a fatal complication in patients who undergo hematopoietic progenitor transplantation (HPT). We present the case of a woman who suffered respiratory failure with bilateral infiltrates on a chest X-ray taken on day ؉14 following autologous bone marrow transplantation. We managed the patient satisfactorily with noninvasive ventilation, avoiding OTI. We believe that patients with non-progressive pulmonary lesions and without multiple system organ failure, may be correctly managed with noninvasive positive-pressure ventilation (NPPV). Keywords: noninvasive ventilation; respiratory failure; hematopoietic progenitor transplantation Respiratory failure (RF) requiring OTI and MV is almost always a fatal complication in patients who undergo hematopoietic progenitor transplantation (HPT), with a global 6 month survival rate between 2 and 5%. [1] [2] [3] [4] [5] In the past few years, the use of noninvasive positive-pressure ventilation (NPPV) has been introduced to treat patients with RF of different etiologies. We therefore considered this a potentially useful strategy in patients who undergo HPT and develop RF. We present the case of a patient who developed severe RF on day ϩ14 post HPT, and in whom NPPV with bilevel airway pressure (BiPAP) was used with good outcome.
Respiratory failure (RF) requiring OTI and MV is almost always a fatal complication in patients who undergo hematopoietic progenitor transplantation (HPT), with a global 6 month survival rate between 2 and 5%. [1] [2] [3] [4] [5] In the past few years, the use of noninvasive positive-pressure ventilation (NPPV) has been introduced to treat patients with RF of different etiologies. We therefore considered this a potentially useful strategy in patients who undergo HPT and develop RF. We present the case of a patient who developed severe RF on day ϩ14 post HPT, and in whom NPPV with bilevel airway pressure (BiPAP) was used with good outcome.
Case report
A 68-year-old white female without outstanding antecedents was diagnosed with diffuse large cell lymphoma stage IVB in March of 1996. She received eight chemotherapy cycles with cyclophosphamide, vincristine, doxorubicin and prednisone, achieving complete remission for 6 ϩ cells/kg were infused. She developed fever during the neutropenic period (day ϩ3) with grade IV mucositis, and empirical antibiotic treatment was started with ceftazidime 2 g/8 h i.v., amikacin 500 mg/12 h i.v. for 2 days and vancomycin 500 mg/6 h i.v. Routine cultures were persistently negative. On day ϩ10, due to the persistence of fever, amphotericin B 70 mg/24 h i.v. was added to the empirical treatment. From day ϩ3 to day ϩ13 although the patient gained 11 kg in weight, her central venous presure (CVP) increased to 25 cm H 2 O, peripheral edema appeared, and albumin levels dropped from 35 g/l to 29 g/l. Chest X-ray was normal. On day ϩ12 haematopoietic recovery began (700 neutrophils). The patient received total parenteral nutrition from day ϩ7 to day ϩ17.
One day ϩ14, she developed sudden dyspnea, tachypnea and RF with a PO 2 /FiO 2 ratio of 135 and bilateral infiltrates on chest X-ray. Diuresis therapy was intensified and inotropic support was added (dopamine at 4 g/kg/min and dobutamine at 9 g/kg/min). Although her fluid balance became negative and the CVP decreased to 12 cm H 2 O, on day ϩ15 X-ray and respiratory function deteriorated (FiO 2 of 0.7 PO 2 of 51 mmHg, 85% saturation and respiratory rate of 48) and MV with BiPAP was initiated, with an 0.8 FiO 2 , 17 cm H 2 O of inspiratory positive-airway pressure (IPAP) and 5-6 cmH 2 O of expiratory positive-airway pressure (EPAP), achieving a tidal volume of 600-700 ml. Her oxygen saturation increased to 99% and respiratory rate decreased to 22. Over the following 3 days pulmonary function improved and PO 2 /FiO 2 increased to 252, allowing a FiO 2 decrease to 0.4 on day ϩ17 and EPAP to 3 cm H 2 O on day ϩ19. On day ϩ20, we alternated BiPAP (with 0.3 of FiO 2 3 cm H 2 O of EPAP and 12 cm H 2 O of IPAP) with 0.6 O 2 by face mask. On day ϩ20, with a negative accumu-lated balance of 171, the BiPAP was removed and replaced with 0.5 O 2 by face mask. The main complication during NPPV was facial skin necrosis that resolved a few days after the BiPAP was stopped. Chest X-rays improved gradually beginning on day ϩ19, although bilateral infiltrates persisted until day ϩ35. On day ϩ24 fever disappeared and the antibiotics were gradually stopped. All cultures were negative. The patient was discharged on day ϩ37.
Discussion
We describe a patient who developed severe RF on day ϩ14 post HPT that resolved without the need for OTI, using NPPV for 6 days. Survival rates at 6 months post OTI due to RF secondary to a pulmonary lesion in patients who undergo HPT are 3-5% regardless of etiology. [1] [2] [3] [4] [5] The etiology of pulmonary lesions in patients who undergo HPT is complex and multifactorial. Lee et al 6 described a situation known as engraftment syndrome (ES) characterised by bilateral pulmonary infiltrates, hypoxia, non-infectious fever, and capillary leak syndrome -which in itself can produce hypoalbuminemia of up to 90% basal level and a weight gain of 105% over basal -on days when haematopoietic recovery takes place. This ES is thought to be caused by the liberation of cytokines during the engraftment process. The prognostic implications of this syndrome are unknown. The RF of our patient could be partially due to this ES and partially due to bilateral heart failure.
Recently, the use of NPPV in the treatment of respiratory failure has become a common practice, 7 in order to avoid OTI. We chose BiPAP with a facial mask because respiratory effort can be decreased by the pressure support and the end-expiratory pressure is useful to treat pulmonary distress and edema. We maintained continuous BiPAP for 5 days and intermittent BiPAP for 1 day. The procedure was well tolerated, causing only facial skin necrosis as a complication, which has been reported in 2-18% of patients. 7 The use of NPPV allowed us to keep the patient in a conventional room supervised by the haematologist in charge of the HPT, thus avoiding the need for transfer to an intensive care unit.
Crawford et al 5 presented a series of 1482 patients who underwent HPT, 348 of whom were subjected to OTI, and they concluded that these patients should not be admitted to the ICU due to high post OTI (97%) mortality. FaberLangendoen et al 4 with a series of 653 patients, 191 of whom were subjected to OTI, recommended that patients not be intubated if they were older than 40 years or if RF began before day ϩ90 post HPT. In these series, no correlation was found between patient survival rate, once intubated, and the conditioning regimen, development of graftversus-host disease, underlying disease, allogeneic vs autologous HPT, or origin of the pulmonary lesion causing RF. The largest and most recent study on BMT patients undergoing MV is that of Rubenfeld et al, 8 which attempts to establish mortality predictors in these patients so as to identify -during the first 4 days of MV -patients who will survive. The study concludes that there are no survivors among patients who have suffered lung injury (PEEP Ͼ5 cm H 2 O or FiO 2 Ͼ0.6 after the first 24 h of MV) and have either required more than 4 h of vasopressor support (dopamine Ͼ5 g/kg/min, norepinefrine or epinefrine) or have sustained hepatic and renal failure (bilirubin Ͼ68 mol/l, creatinine Ͼ177 mol/l during the first 3 days of MV).
Therefore, OTI indications in a patient who undergoes HPT are controversial. The poor prognosis of these patients mitigates against OTI and MV, but, on the other hand, patients requiring OTI are young, disease-free and develop RF due to complications of therapy. Patients who fail NPPV due to progression of pulmonary lesions or multiple organ failure are probably in the bad prognosis group described by Rubenfeld. This is a difficult group about which to make decisions, and each centre should to come to a consensus according to its results after OTI. We believe that patients with non-progressive pulmonary lesions and without multiple system organ failure, such as the patient presented in this case report, can be adequately managed with NPPV.
